Despite a sluggish start, Japan’s biosimilar market looks set for accelerated growth. The country’s patient co-pay dynamic, financial incentives, and commercial model will be keys to success.
Understanding the opportunity in Japan’s biosimilar market
No comments:
Post a Comment